By the time a drug enters the clinical trial phase of testing on humans,
A. its approval is virtually assured.
B. its safety and effectiveness are no longer major concerns.
C. an average of five years of the overall patent life has already expired.
D. it has already completed most of the investment in research and development.
E. the only step left in the process is testing to see if the drug accomplishes its intended
purpose.